323,268 Shares in Repligen Corporation $RGEN Bought by Primecap Management Co. CA

Primecap Management Co. CA acquired a new position in shares of Repligen Corporation (NASDAQ:RGEN) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 323,268 shares of the biotechnology company’s stock, valued at approximately $44,107,000.

A number of other institutional investors also recently bought and sold shares of RGEN. Price T Rowe Associates Inc. MD boosted its stake in shares of Repligen by 31.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company’s stock worth $753,603,000 after buying an additional 1,091,683 shares during the period. United Capital Financial Advisors LLC acquired a new position in Repligen in the 3rd quarter valued at about $368,387,000. Opti Capital Management LP acquired a new position in Repligen in the 4th quarter valued at about $2,399,209,000. Wasatch Advisors LP raised its stake in Repligen by 27.9% during the 2nd quarter. Wasatch Advisors LP now owns 1,590,251 shares of the biotechnology company’s stock valued at $216,974,000 after acquiring an additional 346,720 shares during the last quarter. Finally, Maverick Capital Ltd. purchased a new stake in Repligen during the 1st quarter valued at approximately $178,946,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CFO Jason K. Garland sold 733 shares of the company’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $145.00, for a total transaction of $106,285.00. Following the completion of the transaction, the chief financial officer owned 19,359 shares of the company’s stock, valued at $2,807,055. This represents a 3.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.60% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on RGEN shares. Wells Fargo & Company lifted their target price on Repligen from $180.00 to $185.00 and gave the company an “overweight” rating in a research note on Thursday, July 30th. Zacks Research raised shares of Repligen from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 30th. Benchmark raised Repligen from a “hold” rating to a “buy” rating and set a $185.00 price objective for the company in a research note on Tuesday, July 7th. Royal Bank Of Canada initiated coverage on shares of Repligen in a report on Thursday, May 14th. They set an “outperform” rating and a $160.00 target price for the company. Finally, HSBC cut their price target on Repligen from $170.00 to $150.00 and set a “buy” rating for the company in a report on Wednesday, June 3rd. Three investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $166.43.

Repligen Trading Down 0.8%

Shares of RGEN opened at $180.30 on Thursday. The stock has a fifty day moving average of $150.11 and a two-hundred day moving average of $132.51. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.64 and a current ratio of 9.05. The company has a market capitalization of $10.18 billion, a PE ratio of 246.99, a price-to-earnings-growth ratio of 3.32 and a beta of 1.03. Repligen Corporation has a fifty-two week low of $100.99 and a fifty-two week high of $188.73.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.09. The business had revenue of $204.13 million for the quarter, compared to analysts’ expectations of $201.59 million. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The business’s revenue was up 11.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. As a group, analysts forecast that Repligen Corporation will post 2.06 EPS for the current year.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.